Background: The overexpression of the chemokine receptor 4 (CXCR4) in different epithelial, mesenchymal, and hematopoietic cancers makes CXCR4 an attractive diagnostic and therapeutic target. However, targeting the CXCR4 receptor with small cyclic pentapeptide-based radiopharmaceuticals remains challenging because minor structural modifications within the ligand-linker-chelate structure often significantly affect the receptor affinity. Based on the excellent in vivo properties of CXCR4-directed pentapeptide [
Background
The chemokine receptor 4 (CXCR4) and its sole known natural ligand stromal cell derived factor-1 (SDF-1, CXCL12) are physiologically involved in leukocyte recruitment, homing, and retention of hematopoietic stem and progenitor cells [1, 2] . CXCR4 also holds a substantial role in various pathological conditions and represents a highly attractive therapeutic target. Overexpression of CXCR4 has been linked to cancer proliferation, cell migration, and tissue-specific homing of cancer cells as well as resistance to conventional and targeted therapies [3] [4] [5] .
After the identification of CXCR4 as a co-receptor for the entry of the HIV virus [6] , great efforts have been made towards the development of CXCR4 antagonists. Recently, our group has developed [ Fig. 1 ), a cyclic pentapeptide with 5 nM affinity and high selectivity towards hCXCR4 [7, 8] . [ 68 Ga]pentixafor exhibits high uptake and long retention in CXCR4-expressing tissues (6.16 % ± 1.16 % ID/g, 1 h post-injection (p.i.) and 4.63 % ± 1.54 %, 2 h p.i. in OH1 human small cell lung cancer tumor-bearing mice) and is rapidly cleared from non-target tissue (1.08 % ± 0.27 % in the blood, 1 h p.i.) and renally excreted [7] ; the corresponding tumor-to-blood and tumor-to-muscle ratios are substantially higher than those compared to other peptidic CXCR4 imaging agents [8] . First, studies in patients suffering from lymphoproliferative diseases [9, 10] demonstrated its excellent properties, including a favorable dosimetry for CXCR4-receptor mapping by means of positron emission tomography (PET) [11] .
Based on the success of [ 68 Ga]pentixafor, this study aims to broaden the potential spectrum of radiometallabeled CXCR4 ligands, both for imaging and therapy, by development and in vitro evaluation of a range of tracers labeled with alternative radionuclides, such as 111 In 3+ (for single photon emission computed tomography (SPECT)); 18 However, the experiences gained during the development of pentixafor have shown that, compared with [ 68 Ga]pentixafor, unlabeled pentixafor and other radiometalated pentixafor derivatives exhibit significantly lower CXCR4 receptor affinities. Thus, in contrast to other peptides, such as somatostatin receptor (SSTR), gastrin-releasing peptide receptor (GRPR), or α v β 3 binding peptides, the affinity of [
68 Ga]pentixafor towards CXCR4 is determined by the entire ligand-spacerchelator-radiometal construct. Consequently, a more or less independent "bioactive substructure" or "pharmacophor" (e.g., the pentapeptide core A depicted in Fig. 1 ) cannot be identified. In this study, we investigated pentixafor derivatives with alternative cyclic and acyclic ) column (CS GmbH, Langerwehe, Germany) using a Sykam gradient HPLC System (Sykam GmbH, Eresing, Germany). For elution, linear gradients of acetonitrile (0.1 % (v/v) trifluoroacetic acid (TFA), solvent B) in water (0.1 % TFA (v/v), solvent A) at a constant flow of 1 mL/min over 15 min were used. UV detection was performed at 220 and 254 nm using a 206 PHD UV-vis detector (LinearTM Instruments Corporation, Reno, USA). Purities were determined at 220 nm using LabSolutions software by Shimadzu Corp. Preparative RP-HPLC was performed on a Sykam gradient HPLC System (Sykam GmbH, Eresing, Germany) equipped with a Multospher 100 RP 18-5 (250 × 20 mm 2 ) column (CS GmbH, Langerwehe, Germany) at a constant flow of 10 mL/min using the same solvents as stated above (duration of gradient, 20 min). Electrospray ionization (ESI)-mass spectra were recorded on a Varian 500-MS IT mass spectrometer (Agilent Technologies, Santa Clara, USA).
General SPPS
Peptides were synthesized manually on solid TCP support using standard Fmoc strategy and an Intelli-Mixer syringe shaker (Neolab, Heidelberg, Germany). For Fmoc-deprotection, the peptide was treated with 20 % piperidine in N-methyl-2-pyrrolidone (NMP) (v/v) for 20 min.
For general coupling of amino acids, a solution of Fmoc-Xaa-OH (1.5 equiv), TBTU (1.5 equiv), HOBt (1.5 equiv), and N,N-diisopropylethylamine (DIPEA) (5 equiv) in NMP (1 mL/g resin) was added to the resin-bound peptide and shaken for 90 min at room temperature and washed six times with NMP.
Synthesis of A
The peptide was synthesized according to a previously published procedure [12] . In short, synthesis was carried out using a standard Fmoc strategy using a TCP resin as solid support and HOBt/TBTU as coupling reagents. After selective N-methylation of D-Orn, D-Tyr was coupled to the peptide with HATU/HOAt, cleaved from the resin, and finally cyclized.
Coupling AMB to the D-Orn side chain was carried out using Fmoc-or Boc-protected AMB (1.5 equiv). AMB was preactivated with DIC (N,N′-diisopropyl-carbodiimide) (1.5 equiv), HOAt (1.5 equiv), and DIPEA (4.5 equiv) in 5 mL DMF for 10 min. The D-Orn deprotected peptide precursor was dissolved in DMF, and the preactivated linker was added. After complete reaction 
Coupling of chelators and metal complexation
A molar excess of the activated chelator was added to a free amino group of the peptide analog. Subsequent to successful coupling, the chelator-conjugated peptide was deprotected and purified. Metal complexation was performed in the presence of weakly chelating acetate buffers to reduce the likelihood of hydrolysis. Solutions for metal labeling comprised LuCl 3 (20 mM), pH = 6.0; InCl 3 (20 mM), pH = 4.5; and YCl 3 (20 mM), pH = 5.9, each in ammonium acetate (0.1 M) and Ga(NO 3 ) 3 (2 mM) pH = 3.0; Cu(OAc) 2 pH = 6.0; and ZrCl 4 (20 mM) pH = 1.3, each in water. The chelator-conjugated peptide (250 μL, 2 mM, 1 equiv) was dissolved in H 2 O and DMSO up to 50 % (v/v), if necessary, and the metal (1-10 equiv) was added, pH adjusted, and heated for 30 min. Final metalated peptides were obtained in a purity ≥ 95 %, and used for in vitro studies without further purification, unless stated otherwise.
Coupling of DOTA or NOTA
For DOTA/NOTA derivatization, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) or 1,4,7-triazacyclononane-triacetic acid (NOTA) (1 equiv) was preactivated for 20 min using N-hydroxysuccinimide (NHS) (1.25 equiv), 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDCI) (1.25 equiv), and DIPEA (2 equiv) dissolved in water (1 mL/0.3 mmol). The peptide B (0.25 or 0.3 equiv, for DOTA or NOTA, respectively) was dissolved in DMF (1 mL per 0.15 mmol of peptide) and slowly added to the reaction mixture according to a previously published protocol [13] . Coupling of DTPA 3,6,9-tris(2-(tert-butoxy)-2-oxoethyl)-13,13-dimethyl-11-oxo-12-oxa-3,6,9-triazatetradecan-1-oic acid (DTPA)(tBu) 4 (2 equiv) was coupled to B (1 equiv) using a solution of DIC (1.5 equiv), HOAt (1.5 equiv), and DIPEA (4.5 equiv) in anhydrous DMF. After successful coupling, the product was deprotected and purified. HPLC Cell culture and determination of CXCR4 receptor affinity (IC 50 )
For in vitro experiments, the Jurkat T -cell line was used. The cells were maintained in RPMI 1640 medium (Biochrom) containing 10 % fetal calf serum (FCS) (Biochrom). The cell line was cultured at 37°C in a humidified atmosphere with 5 % CO 2 and passaged two to three times a week, depending on the cell count. CXCR4 affinities were determined in competitive binding assays using Jurkat cells with [
125 I]FC131 as the radioligand according to a protocol similar to previously published [7] . FC131 (cyclo(-D-Tyr-L-Arg-L-Arg-L-NalGly-)) [14] was synthesized and iodinated as described previously [7] . Jurkat cells (4 × 10 5 cells per vial) were incubated with the respective peptide of interest at the final concentrations ranging from 10 −11 to 10 −5 M and app. 0.1 nM of [ 125 I]FC131. The total sample volume was 250 μL. After an incubation time of 120 min, the vials were centrifuged at 1300 rpm (Heraeus Megafuge, Thermo) for 3 min and the supernatant was removed. The cells were washed twice with 200 μL ice-cold Hank's balanced salt solution (HBSS). After each washing step, the samples were centrifuged and the supernatant removed. Finally, the amount of displaced and bound radioligand in the combined fractions of the supernatant and the cell pellet was quantified. The half maximal inhibitory concentration (IC 50 ) values were determined using GraphPad Prism software.
Results

Based on the promising results of [
68 Ga]pentixafor [7] [8] [9] [10] [11] 15] , the influence of different pentixafor-based peptidelinker-chelators on the CXCR4 affinity (IC 50 ) has been evaluated. For this purpose, seven different chelators have been coupled via an AMB moiety to the D-Orn side chain of the CPCR4.2 core peptide A (Fig. 1): (a) DOTA, (b)  DOTAGA, (c) NOTA, (d) 1,4 ,7-triazacyclononane,1-glutaric acid-4,7-acetic acid (NODAGA), (e) DTPA, (f) p-SCNBn-DTPA, (g) p-SCN-Bn-Desferrioxamine (DFO), and (h) p-SCN-Bn-NODA, whereby SCN-Bn-NODA was directly coupled to the pentapeptide core without ABS. Depending on the preferred metals for each chelator, reference Ga (Table 1) .
As already demonstrated [7, 8] , non-metalated pentixafor (1) shows low affinity (IC 50 : 102 ± 17 nM) towards CXCR4, whereas the Lu 3+ and Y 3+ complexes (IC 50 : 40.9 ± 12 and 40.8 ± 27 nM, respectively) exhibit affinities quite similar to [
nat In]pentixafor (IC 50 : 44 ± 4 nM) [7] . Surprisingly, the affinity of the Bi 3+ complex is even higher (IC 50 : 22.1 ± 7.0 nM) than the affinity of [
nat Ga]-pentixafor (IC 50 : 24.6 ± 2.5 nM) thus making [
213 Bi]pentixafor an attractive α-particle emitting therapeutic analog for endoradiotherapy. The affinity of the corresponding Cu 2+ complex was low (131 ± 11 nM). With regard to previous reports [7] , it is important to notice that absolute IC 50 values for [
nat Ga]pentixafor differ because higher cell numbers were used for the IC 50 experiments in this study ( 
Discussion
Experiences in the development of CXCR4-targeting peptides showed that affinities to the CXCR4 receptor can be significantly affected by even moderate structural modifications in the pentapeptide core [16] [17] [18] [19] , the linker unit [20] , or the chelate [7, 8] . This is in contrast to previous experiences of GPCR, glycoprotein, or enzymetargeting peptides, such as SSTRs, GRPRs (bombesin), and integrins (e.g., αvß 3 , RGD peptides), as well as the prostatespecific membrane antigen (PSMA), to mention only a few. A variety of peptides towards these targets have been developed and-unlike CXCR4-conjugated with a broad spectrum of linker/chelator moieties. For αvß 3 -binding RGD peptides, the Lys side chain of the typically used c(Arg-Gly-Asp-D-Phe-Lys) does not influence the binding of the peptide in the cleft between the two α v and β 3 subunits that forms the heterodimeric transmembrane glycoprotein [21] . Thus, these RGD peptides tolerate the introduction of spacers and chelator or the formation of multimers, such as dimers, tetramers, and octamers [22, 23] . Similar freedom of variation, although not that multifarious, has been found for SST ligands. Y. All conjugates, including metal-free octreotate bound hSST2 with high affinity (0.2 to 3.9 nM), regardless of the chelator and metal used [24] . This was confirmed by other SST2 binding peptides, coupled to NODAGA, CB-TE2A, or DOTA and labeled with nat Ga or nat Cu resulting in affinities in a range from 1.3 to 12.5 nM [25] . Moreover, modification of [33, 34] and other further 68 Ga-tracers developed by Eder et al. [35, 36] .
Although different groups used different models for affinity evaluation, the relative trend shows that, in contrast to the examples above, the CXCR4 affinity is strongly influenced by the entire ligand-spacer-chelatorradiometal construct. During the development of linkerbridged dimers, Demmer et al. could demonstrate that even dimers, consisting of one high affinity and one "non-" CXCR4-binding peptide exhibit higher affinity when compared with the high affinity monomer conjugated with the used linker [20] . The authors conclude a subsite binding of the second peptide unit close to the main binding pocket. ]3 significantly contributes to and is a prerequisite for high affinity binding of the entire peptide ligand. Consequently, depending on the chelator, metalation can have a significant effect on the affinity towards CXCR4.
Conclusions
In summary, these studies demonstrated that pentixafor, consisting of the cyclic peptide cyclo(-D-Tyr-N-Me-DOrn-L-Arg-L-2-Nal-Gly-) and conjugated at the Orn side chain with AMB-[ 
